Compare CRSP & SEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | SEB |
|---|---|---|
| Founded | 2013 | 1918 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Farming/Seeds/Milling |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.9B |
| IPO Year | 2016 | 1994 |
| Metric | CRSP | SEB |
|---|---|---|
| Price | $60.11 | $5,082.03 |
| Analyst Decision | Buy | |
| Analyst Count | 17 | 0 |
| Target Price | ★ $70.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 19.3K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 0.18% |
| EPS Growth | N/A | ★ 467.71 |
| EPS | N/A | ★ 514.46 |
| Revenue | $289,590,000.00 | ★ $5,809,000,000.00 |
| Revenue This Year | $1,603.19 | N/A |
| Revenue Next Year | $78.75 | N/A |
| P/E Ratio | ★ N/A | $9.72 |
| Revenue Growth | ★ 9169.85 | 7.99 |
| 52 Week Low | $30.06 | $2,437.00 |
| 52 Week High | $78.48 | $5,654.00 |
| Indicator | CRSP | SEB |
|---|---|---|
| Relative Strength Index (RSI) | 61.24 | 54.62 |
| Support Level | $58.40 | $4,252.56 |
| Resistance Level | $60.40 | $5,654.00 |
| Average True Range (ATR) | 3.03 | 222.28 |
| MACD | 1.16 | -48.52 |
| Stochastic Oscillator | 86.78 | 39.88 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Seaboard Corp is a diversified group of companies that operate in agricultural, energy, and ocean transport businesses. The company is engaged in hog production, biofuel production, and pork processing in the United States; commodity trading and grain processing in Africa and South America; cargo shipping services in the U.S., Caribbean and Central and South America; sugar and alcohol production in Argentina; and electric power generation in the Dominican Republic. It also has an equity method investment in Butterball, LLC, a producer and processor of turkey products. The group's operating segments are; pork, commodity trading and milling, marine, liquid fuels, power, turkey, and others. It operates in 45 countries, with a concentration in the Caribbean, Central and South American region.